Tremfya, also known as guselkumab, is a prescription drug made by Johnson & Johnson to treat inflammatory skin and joint diseases. It works by blocking interleukin-23 (IL-23), which decreases inflammation within the immune system. According to Polaris Market Research, the global Tremfya market was valued at USD 4.2 billion in 2025, is estimated at USD 4.51 billion in 2026, and is projected to reach USD 7.99 billion by 2034, registering a CAGR of 7.40% from 2026 to 2034.

What Is Driving Demand

The report links growth to an increasing preference for biologic therapies over traditional systemic treatments, rising healthcare spending, and improved access to specialty medicines. A further driver is the rising number of people diagnosed with chronic psoriasis and psoriatic arthritis, long-term autoimmune conditions that require ongoing treatment. A 2024 study in Acta Dermato-Venereologica reported that, among psoriasis patients in Korea, PsA prevalence increased from 6.17 per 1,000 patients in 2008 to 19.03 per 1,000 in 2020, indicating a growing pool of patients who need specialized treatment.

How Tremfya Differs from Traditional Treatments

The report contrasts Tremfya's targeted IL-23 inhibition with the broad immune suppression of traditional treatments. Tremfya is a biologic given by subcutaneous injection, with maintenance dosing every 8 weeks after initial loading doses, and it is used under specialist supervision in dermatology and immunology clinics. Traditional options include topicals, phototherapy, and systemic drugs, often dosed daily or weekly.

Segment Leadership

By application, the plaque psoriasis segment held the largest share of 85.31% in 2025, because it is the most common form of psoriasis. The report cites the National Psoriasis Foundation estimate that 2% to 3% of the global population, or 125 million people, are affected by psoriasis. The PsA segment is anticipated to register the highest growth rate, driven by rising awareness and diagnosis. Phase 3b APEX study data announced by Johnson & Johnson on June 11, 2025 showed that Tremfya significantly inhibited the progression of joint structural damage in active PsA.

By distribution channel, hospital pharmacies led with a 51.52% share in 2025, owing to the specialized handling, storage, and administration that biologics require. Hospitals also house the specialists who prescribe these treatments, creating a direct pathway from diagnosis to dispensation.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/tremfya-market 

Market Characteristics

The market is research-driven, with continuous advances aimed at improving efficacy, minimizing adverse effects, and offering less frequent dosing. Entry barriers are high because of the complexity of biologic development, including stringent manufacturing protocols, cold-chain logistics, and advanced biotechnological infrastructure. Regulators such as the US FDA and the European Medicines Agency enforce rigorous standards for biologics, requiring ongoing post-marketing surveillance and safety monitoring.

Regional Analysis

North America dominated with a 41.22% share in 2025, supported by a high prevalence of chronic inflammatory conditions, well-developed healthcare infrastructure, and high adoption of biologics. The U.S. led the region with an 83.12% revenue share, helped by awareness among dermatologists and rheumatologists. Europe is described as a substantial and growing region, with Germany standing out as a key country. Asia Pacific is expected to record the highest CAGR of 10.8% during the forecast period, as governments invest more in healthcare infrastructure, with Japan driving much of the regional growth.

Key Player in the Tremfya Market

Johnson & Johnson continues to dominate the market through its immunology experience, strong commercialization capabilities, and relationships with healthcare providers worldwide. The report names the following key player:

• Johnson & Johnson

Conclusion

The Tremfya market is shaped by a large and growing patient base, a targeted mechanism of action, and strong specialist-led distribution. North America leads today, and Asia Pacific offers the fastest growth outlook. For stakeholders, clinical evidence, patient awareness, and access to specialty care remain the key variables through 2034.

More Trending Latest Reports By Polaris Market Research:

Oxycodone Drugs Market

Long Read Sequencing Market

Cooling Towers Market

Field Device Management Market

Embedded AI Market

Baking Enzymes Market

Baking Enzymes Market

Cooling Towers Market

Content Delivery Network Market